Apollomics spent the better part of the past year and a half in a near-death episode. By the late summer of that stretch its prior management had announced an expected wind-down of all clinical activity, the Nasdaq Listing Qualifications Staff had moved to delist the company as a "public shell," and a stretch of bid prices below one dollar had already forced a one hundred to one reverse stock split the previous November. The capital structure was thin, the consolidated balance sheet closed that period with a small positive book value, the SPARTA Phase 2 study in glioblastoma was being unwound, and cash on the balance sheet was dwindling into the low single-digit millions. Then a PIPE closed in early September of that year, a new board and executive team were installed, the SPARTA wind-down was reversed, the delisting appeal succeeded, and the company turned its full organizational focus to a single clinical asset: vebreltinib, its oral selective c-Met inhibitor already conditionally or fully approved in China by partner Avistone in three indications through 2025. By the time the FY2025 annual report landed in late April 2026 the net loss for the year had collapsed by roughly 80 percent from the prior year and by more than 90 percent from the year before that, R&D spending had been cut to a small fraction of its earlier level, and the auditor was nonetheless obliged to flag a material-uncertainty going-concern paragraph because of the year-end cash position against an operating plan that runs into 2027.
The story for APLM is therefore a binary turnaround wrapped around a single-asset clinical biotech. On one side stands an emerging Asia-validated c-Met inhibitor with a substantial patient safety database, three Chinese approvals, a fresh partnership revenue line, a global Phase 2 trial that is being reactivated, and a recently installed management team that has just completed a cash PIPE plus a CEO bridge loan conversion at the August 2026 financing. On the other side stands a company that finished 2025 with negative shareholders' equity, a barely adequate Nasdaq market value of listed securities cushion, a previously terminated and now-litigated Asia partnership, an ongoing contract research organization dispute, a multi-program pipeline that has been almost entirely de-prioritized, and an accumulated deficit measured in the hundreds of millions of dollars. The investment debate is whether the vebreltinib program alone, with the cash now in hand and the de-risked Chinese approvals in pocket, can carry the equity to a value above the recent PIPE mark, or whether a future round at a lower mark continues to compress the cap table.
The next twelve months offer three concrete triggers. The first is the resumption of clinical activity in the vebreltinib NSCLC and glioma programs, which is the principal operational datapoint following the death-and-rebirth of the SPARTA Phase 2 study. The second is the FY2026 audit cycle and any additional capital actions, since the FY2025 annual report notes that the company is pursuing further financings but that none are contractually committed. The third is the cluster of small but real overhangs from the contract research organization counterclaim, the Cayman minority-investor litigation, and the residual Asia partner dispute resolution process, each of which can swing the cost of capital at the margin. The trade for APLM is a long-biotech bet on a c-Met inhibitor with a substantial safety database, three foreign approvals, and a freshly reconstituted management team, against the backstop of a balance sheet that required an emergency CEO bridge loan earlier in the year.